Cargando…

Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells

BACKGROUND: Vorinostat, a histone deacetylase (HDAC) inhibitor, is a promising agent for cancer therapy. Combining vorinostat with cisplatin may relax the chromatin structure and facilitate the accessibility of cisplatin, thus enhancing its cytotoxicity. Studies have not yet investigated the effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Chun-Hao, Chang, Ying-Fang, Lee, Ming-Shuo, Wen, B-Chen, Ko, Jen-Chung, Liang, Sheng-Kai, Liang, Mei-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100277/ https://www.ncbi.nlm.nih.gov/pubmed/27821078 http://dx.doi.org/10.1186/s12885-016-2888-7

Ejemplares similares

Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells
por: Liao, Bo, et al.
Publicado: (2017)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells
por: Kwak, Tae Won, et al.
Publicado: (2013)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles
por: Meka, Anand Kumar, et al.
Publicado: (2018)

Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects
por: Liu, Shuangxi, et al.
Publicado: (2019)

Gambogenic acid exerts anticancer effects in cisplatin-resistant non-small cell lung cancer cells
por: Shen, Daofu, et al.
Publicado: (2020)

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma
por: Jeannot, Victor, et al.
Publicado: (2016)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
por: Chao, Min-Wu, et al.
Publicado: (2015)

Radiosensitization effects of curcumin plus cisplatin on non-small cell lung cancer A549 cells
por: Cai, Yong, et al.
Publicado: (2019)

Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line
por: Li, Nainong, et al.
Publicado: (2015)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2015)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

TRIB2 contributes to cisplatin resistance in small cell lung cancer
por: Liang, Yuanxin, et al.
Publicado: (2017)

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
por: Sato, Akinori
Publicado: (2012)

The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells
por: Mu, Xiaodong, et al.
Publicado: (2015)

Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells
por: Kwak, Tae Won, et al.
Publicado: (2015)

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma
por: Gao, Minjie, et al.
Publicado: (2016)

Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells
por: Ma, Xiaoli, et al.
Publicado: (2017)

Lentinan combined with cisplatin for the treatment of non-small cell lung cancer
por: Zhao, Chenchen, et al.
Publicado: (2021)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
por: Lautz, Timothy B., et al.
Publicado: (2012)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

A broad-spectrum antibiotic, DCAP, reduces uropathogenic Escherichia coli infection and enhances vorinostat anticancer activity by modulating autophagy
por: Allavena, Giulia, et al.
Publicado: (2018)

Proteomic Analysis Identified DJ-1 as a Cisplatin Resistant Marker in Non-Small Cell Lung Cancer
por: Zeng, Hua-Zong, et al.
Publicado: (2011)

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
por: Phillip, Cornel J, et al.
Publicado: (2012)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Direct but No Transgenerational Effects of Decitabine and Vorinostat on Male Fertility
por: Kläver, Ruth, et al.
Publicado: (2015)

Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy
por: Zierfuss, Bettina, et al.
Publicado: (2020)

Methotrexate/tacrolimus/vorinostat: Lack of efficacy: case report
Publicado: (2022)

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
por: Stathopoulos, G. P., et al.
Publicado: (2011)

MnTnHex-2-PyP(5+) Displays Anticancer Properties and Enhances Cisplatin Effects in Non-Small Cell Lung Cancer Cells
por: Soares, Rita B., et al.
Publicado: (2022)

Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro
por: XU, XIAO-MAN, et al.
Publicado: (2013)

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
por: Duvic, M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_d3cfjn6h054621nq13ndtn813r